Powering the next era
of RNA medicine

The world's only unified, end-to-end RNA platform.
Design, produce, deliver any RNA candidate, from a single personalized
dose to 50 million doses a day on the same platform

Discover our RNA platform

Quantoom is your full stack RNA partner

Our platform enables anyone to unlock RNA's potential.

Our N-Force platform unifies design, production and delivery into one workflow, so partners move from a sequence/disease to a candidate faster, cheaper, and with freedom to operate built in from day one.

Making RNA therapies affordable, scalable, and accessible worldwide, from mass pandemic response to personalized cancer treatment, with the world's only unified, end-to-end RNA platform.

The N-Force toolbox

Design. Produce. Deliver.

End-to-end RNA platform, based on three integrated components, covering the full value chain to accelerate RNA development & manufacturing.

Ncode
Ncode
RNA sequence design

AI-driven proprietary algorithms that optimize RNA sequences for stability, protein expression, and, critically, manufacturability.

Explore Ncode
Ntensify
Ntensify®
RNA production

Automated construct-agnostic process embedded into equipment and reagent kits that scale from milligrams to kilograms with no re-engineering.

Explore Ntensify®
Ncapsulate
Ncapsulate®
RNA formulation chemistry

Best-in-class delivery built on proprietary lipid-like chemistry — matching best-in-class performance with freedom-to-operate built in, at a fraction of incumbent licensing costs.

Explore Ncapsulate®
Why Quantoom?

What it means for you

Five levers of the N-Force platform. Hover or tap a lever to see how it changes the economics of an RNA program.

−18 months

cut from process development

Turnkey workflows drastically reducing the development timeline per program.

Track record

Proven across pre-clinical and target-species evaluation

The N-Force platform has been evaluated across multiple in vivo studies and provides preclinical evidence.

In vivo functionality acrossmultiple animal models

Versatility acrossmodalities and applications

Exploratory tolerability(pre-GLP)

28RNA production systems sold worldwide
45+clients
27countries
Cancer treatment
RNA
CNP
Sequence design & optimization
RNA/formulation preparation
In vitro testing
Preclinical
Clinical
Partners
mRNA
QCX-002
Ncode
Melanoma (shared antigen)
Serum Institute of India
mRNA
QCX-002
Ncode
Melanoma (neoantigen)
Arizona State University
mRNA
QCX-002
Ncode
Colorectal (neoantigen)
Oxford Cancer
mRNA
QCX-002
Ncode
CAR-T
Undisclosed partner
Human vaccines
RNA
CNP
Sequence design & optimization
RNA/formulation preparation
In vitro testing
Preclinical
Clinical
Partners
mRNA
REF CNP
Ncode
Rabies
Internal program
mRNA
REF CNP
Ncode
COVID-19 & Influenza
Horizon Europe
saRNA
QCX-002
Ncode
Influenza H5N1
Serum Institute of India
mRNA
REF CNP
Ncode
Malaria
European Vaccine Initiative
Animal vaccines
RNA
CNP
Sequence design & optimization
RNA/formulation preparation
In vitro testing
POC in target species
Early-phase development
Partners
sa/mRNA
QCX-002
Ncode
PPRV
CVIMThe Pirbright Institute
saRNA
QCX-002
Ncode
Avian Influenza, HPAI
VaxThera
mRNA
QCX-002
Ncode
Feline cancer
Feline cancer
Undisclosed partner
mRNA
QCX-002
Ncode
Inf. disease
Undisclosed partner
Trusted by leading research organizations
University of Naples Federico II
CNC — Center for Neuroscience and Cell Biology
University of Western Australia
University of California, Berkeley
CVIM
The Pirbright Institute
VaxThera
Bio-Manguinhos / Fiocruz
Afrigen Biologics & Vaccines
National Vaccine Institute Ghana
University of Tartu
Oxford Cancer

Explore further

Ready to reinvent your RNA program?

Talk to our team about how the N-Force toolbox can compress your timelines from sequence to dose.

Book a call →